Hostname: page-component-74656f9884-rdgjk Total loading time: 0 Render date: 2026-11-07T06:53:05.747Z Has data issue: false hasContentIssue false

FhCaBP2: a Fasciola hepatica calcium-binding protein with EF-hand and dynein light chain domains

Published online by Cambridge University Press:  08 July 2015

CHARLOTTE M. THOMAS
Affiliation:
School of Biological Sciences, Queen's University Belfast, Medical Biology Centre, 97 Lisburn Road, Belfast BT9 7BL, UK Institute for Global Food Security, Queen's University Belfast, 18-30 Malone Road, Belfast BT9 5BN, UK
DAVID J. TIMSON*
Affiliation:
School of Biological Sciences, Queen's University Belfast, Medical Biology Centre, 97 Lisburn Road, Belfast BT9 7BL, UK Institute for Global Food Security, Queen's University Belfast, 18-30 Malone Road, Belfast BT9 5BN, UK
*
* Corresponding author. School of Biological Sciences, Queen's University Belfast, Medical Biology Centre, 97 Lisburn Road, Belfast BT9 7BL, UK. E-mail: d.timson@qub.ac.uk

Summary

FhCaBP2 is a Fasciola hepatica protein which belongs to a family of helminth calcium-binding proteins which combine an N-terminal domain containing two EF-hand motifs and a C-terminal dynein light chain-like (DLC-like) domain. Its predicted structure showed two globular domains joined by a flexible linker. Recombinant FhCaBP2 interacted reversibly with calcium and manganese ions, but not with magnesium, barium, strontium, copper (II), colbalt (II), iron (II), nickel, lead or potassium ions. Cadmium (II) ions appeared to bind non-site-specifically and destabilize the protein. Interaction with either calcium or magnesium ions results in a conformational change in which the protein's surface becomes more hydrophobic. The EF-hand domain alone was able to interact with calcium and manganese ions; the DLC-like domain was not. Alteration of a residue (Asp-58 to Ala) in the second EF-hand motif in this domain abolished ion-binding activity. This suggests that the second EF-hand is the one responsible for ion-binding. FhCaBP2 homodimerizes and the extent of dimerization was not affected by calcium ions or by the aspartate to alanine substitution in the second EF-hand. The isolated EF-hand and DLC-like domains are both capable of homodimerization. FhCaBP2 interacted with the calmodulin antagonists trifluoperazine, chlorpromazine, thiamylal and W7. Interestingly, while chlorpromazine and thiamylal interacted with the EF-hand domain (as expected), trifluoperazine and W7 bound to the DLC-like domain. Overall, FhCaBP2 has distinct biochemical properties compared with other members of this protein family from Fasciola hepatica, a fact which supports the hypothesis that these proteins have different physiological roles.

Information

Type
Research Article
Copyright
Copyright © Cambridge University Press 2015 
Figure 0

Fig. 1. The predicted structure of FhCaBP2. (A) The predicted overall fold is shown in orange with a calcium ion (yellow) ball shown at the second EF-hand in the N-terminal domain. (B) Close-up views of the two EF-hands showing the potential ion-binding residues. Only the second EF-hand is shown to be interacting with a calcium ion, consistent with the data reported in this paper. (Colour version available online).

Figure 1

Fig. 2. Expression and purification of FhCaBP2 and its domains. Expression in, and purification of, recombinant proteins from E. coli was monitored by SDS-PAGE (10% for full length FhCaBP2 and 15% for the EF-hand and DLC-like domains). M, molecular mass markers (sizes shown to the left of the gel in kDa); U, extract from uninduced cells immediately prior to induction with IPTG; I, extract from induced cells immediately prior to harvesting; S, soluble material after sonication and centrifugation of cell extracts; F, material which flowed through the column; W, material removed from the column by washing; E1, E2 and E3, first, second and third elutions. For details of the purification methods, see Materials and Methods.

Figure 2

Fig. 3. Ion-binding by FhCaBP2 and its domains as revealed by native gel electrophoresis. In each case protein (50 μm) was resolved on 10% native polyacrylamide gels. The first lane contained the untreated protein (U) and the second protein incubated with EGTA (1 mm). The remaining lanes contained protein in the presence of EGTA (1 mm) and the indicated ion (2 mm).

Figure 3

Fig. 4. Ion-binding by FhCaBP2 and its domains as revealed by DSF and ANS fluorescence. (A) Representative first differential traces showing the thermal denaturation (‘melting’) of FhCaBP2 (10 μm) in EGTA (0·6 mm) and EGTA (0·6 mm)/calcium chloride (1·2 mm). (B) ANS fluorescence spectra of FhCaBP2 (15 μm). (C) ANS fluorescence spectra of the EF-hand domain (15 μm). (D) ANS fluorescence spectra of the DLC-like domain (15 μm). (E) ANS fluorescence spectra of FhCaBP2-D58A (15 μm). (F) ANS fluorescence spectra of EF-D58A (15 μm). In (b)–(f), spectra were obtained in the presence of ANS (30 μm) and EGTA (1 mm, solid black line), EGTA (1 mm)/calcium chloride (2 mm; dashed black line), EGTA (1 mm)/magnesium chloride (2 mm; dotted black line) or EGTA (1 mm)/manganese chloride (2 mm; solid grey line).

Figure 4

Table 1. Stabilization of FhCaBP2 by divalent ions as revealed by DSF

Figure 5

Fig. 5. Dimerization of FhCaBP2 revealed by cross-linking with BS3. FhCaBP2 and its domains (50 μm) were incubated in the without (−) and with (+) of the cross-linking agent BS3 (800 μm) in the presence of the ions indicated. M, molecular mass markers (sizes shown to the left of the gel in kDa); U, untreated protein. All the remaining lanes contained EGTA (1 mm) and, where indicated either calcium, cadmium or manganese chloride (2 mm).

Figure 6

Fig. 6. Drug-binding by FhCaBP2 revealed by limited proteolysis. FhCaBP2 (50 μm) was digested with either chymotrypsin (150 nm) or protease X (50 nm) as described in the Materials and Methods. M, molecular mass markers (sizes: 116, 66, 45, 35, 25, 18, 14 kDa); U, untreated protein; − protein treated with protease in the absence of drugs; DMSO, protein treated with protease in the presence of 1% (v/v) DMSO. In this experiment, all drugs were used at a concentration of 250 μm.

Figure 7

Table 2. Interaction of FhCaBP2 with drugs as revealed by DSF

Supplementary material: File

Thomas and Timson supplementary material

Thomas and Timson supplementary material 1

Download Thomas and Timson supplementary material(File)
File 249.1 KB
Supplementary material: File

Thomas and Timson supplementary material

Thomas and Timson supplementary material 2

Download Thomas and Timson supplementary material(File)
File 248.7 KB
Supplementary material: File

Thomas and Timson supplementary material

Figure S1

Download Thomas and Timson supplementary material(File)
File 69.3 KB